Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation
조혈모세포 이식 환자에서 코로나19의 유리한 결과
Clinical Trial
[키워드] active malignancy
Allogeneic
Antibody Response
antiviral response
autologous
CAR
Cell
cell transplantation
cellular
center
Characteristics
chimeric antigen receptor
clinical
Clinical outcome
clinical variable
composite endpoint
COVID-19
Critical
death
diagnosed
disease
event
identify
immune
investigated
IQR
lymphocyte
Lymphocyte subsets
median time
Memorial
nasopharyngeal swabs
neutropenia
number of comorbidity
outcome
overall survival
Oxygen requirement
Patient
patients
patients with COVID-19
patients with SARS-CoV-2
Population
quantitative real-time PCR
recipient
recipients
reduction
SARS-CoV-2
SARS-CoV-2 antibody
severity
significantly
stem cell
Stem cell transplantation
subset
T cell
T cells
therapy
transplantation
variable
with COVID-19
[DOI] 10.1172/JCI141777 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1172/JCI141777 PMC 바로가기 [Article Type] Clinical Trial